Evidence map›Paper›PMID 34072876›Full record

ArticleJournal of fungi (Basel, Switzerland)2021

Impact of the SARS-CoV-2 Pandemic in Candidaemia, Invasive Aspergillosis and Antifungal Consumption in a Tertiary Hospital.

Juan Vicente Mulet Bayona, Nuria Tormo Palop, Carme Salvador García, Begoña Fuster Escrivá, Mercedes Chanzá Aviñó, Pilar Ortega García, Concepción Gimeno Cardona

Open access · goldAbstract read
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 70 citations in OpenAlex.

  1. Review of the Microbial Spectrum of Mixed Respiratory Fungal Infections.Journal of epidemiology and global health · 2026
    Review
  2. Genomic landscape ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Article
  3. Article
  4. Observational
  5. Review
  6. Virulence Factors and Molecular Identification ofJournal of fungi (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Review
  9. Microorganisms · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Current medical mycology · 2022
    Review
  18. Current medical mycology · 2022
    Article
  19. The Menace ofDiseases (Basel, Switzerland) · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Juan Vicente Mulet BayonaDepartment of Microbiology and Parasitology, Consorcio Hospital General Universitario de Valencia, 46014 Valencia, Spain.ORCID 0000-0003-0678-9068
Nuria Tormo PalopDepartment of Microbiology and Parasitology, Consorcio Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Carme Salvador GarcíaDepartment of Microbiology and Parasitology, Consorcio Hospital General Universitario de Valencia, 46014 Valencia, Spain.ORCID 0000-0002-8577-5934
Begoña Fuster EscriváDepartment of Microbiology and Parasitology, Consorcio Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Mercedes Chanzá AviñóDepartment of Microbiology and Parasitology, Consorcio Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Pilar Ortega GarcíaDepartment of Hospital Pharmacy, Consorcio Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Concepción Gimeno CardonaDepartment of Microbiology and Parasitology, Consorcio Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Hospital General Universitario De Valencia · ESUniversitat de València · ES

Funding

Fundación de Investigación Hospital General Universitario de Valencia 1800
6 · The paper itself

Abstract

In addition to the increase in fungal infections that has been observed in the last few decades, it has been reported that severe clinical COVID-19 can increase the risk of invasive fungal infections. The main objective of this study was to evaluate if there had been an increase in candidaemia and invasive pulmonary aspergillosis (IPA) cases since the onset of the SARS-CoV-2 pandemic. Data were retrospectively collected from April 2019 to March 2021, from patients admitted to Consorcio Hospital General Universitario de Valencia (Spain). A total of 152 candidaemia cases (56 of which were due to

Indexed as

antifungalsaspergillosiscandidaemiaCOVID-19IFIisavuconazole

Identifiers

PMID34072876
PMCPMC8228091
OpenAlexW3165147826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.